Your Journey Starts Here,
Innovative Approaches to the Treatment of Fibrotic Disease
Fighting Fibrosis at its Core.
- Groundbreaking science.
- Targeted therapies.
- A better future for patients.
Groundbreaking Science
Fibrosis is a major cause of morbidity and mortality, affecting organs such as the lungs, liver, kidneys, and heart.
Indalo’s scientific foundation stems from discoveries published in Nature Medicine, revealing the pivotal role of RGD-binding integrins in TGF-β activation, a key regulator of fibrotic progression.
- Elevated expression of RGD-integrins in fibrotic lesions
- Profound anti-fibrotic effects shown in genetic and pharmacologic studies
- Clear therapeutic opportunity in targeting selective integrins.
Cutting-Edge Technology
Indalo’s technology platform develops highly potent, integrin-selective small molecules with oral bioavailability and broad or focused target profiles. Our compounds have demonstrated efficacy in preclinical models of :
- Renal Fibrosis
- Hepatic Fibrosis
- Pulmonary Fibrosis
- Pancreatic and Cardiac Fibrosis
- Post-surgical Implant Fibrosis
Transforming Lives
Bringing Hope to Millions Affected by Fibrotic Diseases.
Innovation
Where breakthroughs in health begin.
Let’s Build the Future of Fibrosis Treatment
Whether you're a scientist, investor, or potential partner, we’d love to hear from you. Let’s work together to change lives.
Contact us